Abstract: | Background: To investigate the clinical value of HE4 detection in the diagnosis of lung cancer and the clinicalsignificance of combined detection with CEA, NSE and CYFRA21-1. Methods: 90 cases of lung cancer, 30 cases ofpulmonary tuberculosis, 30 cases of pneumonia and 30 cases of health physical examination were selected. The levelsof serum HE4, CYFRA21-1, CEA and NSE were detected by electrochemiluminescence method. Statistical analysis wasperformed to observe the sensitivity and specificity. Results: The levels of serum HE4, CEA, NSE and CYFRA21-1 inlung cancer group were significantly higher than those in tuberculosis group and health physical examination group.There was no significant difference in the levels of HE4, CEA and NSE between the lung cancer group and the pneumoniagroup, the difference of CYFRA21-1 level was statistically significant (p<0.05).With health physical examinationgroup as normal controls, the sensitivity and specificity of combined detection of HE4, CEA, NSE and CYFRA21-1 inthe diagnosis of lung cancer were 82.2% and 90.0%,and the area under the curve (AUC) was 0.907, followed by HE4(0.867), CYFRA21-1 (0.787), CEA (0.752) and NSE (0.747). Conclusion: HE4 can be used as a serological marker forthe diagnosis of lung cancer. The combined detection of HE4, CEA, NSE and CYFRA21-1 can improve the diagnosis oflung cancer. Serum HE4 levels are highly specific in distinguishing between lung cancer patients and normal population,and are equivalent to CYFRA21-1; but they are less specific than CYFRA21-1 in distinguishing lung cancer patientsfrom pneumonia patients. |